{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:19:36Z","timestamp":1769221176615,"version":"3.49.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08936-1","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:24:30Z","timestamp":1751361870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Achieving equitable recruitment through inclusive protocol design: lessons learned from the ILANA study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-4101","authenticated-orcid":false,"given":"Rosalie","family":"Hayes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Smuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bakita","family":"Kasadha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishat","family":"Halim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Apea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-2481","authenticated-orcid":false,"given":"Sara","family":"Paparini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6745","authenticated-orcid":false,"given":"Chloe M.","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the ILANA study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"8936_CR1","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1186\/s13063-020-04613-7","volume":"21","author":"MD Witham","year":"2020","unstructured":"Witham MD, Anderson E, Carroll C, Dark PM, Down K, Hall AS, et al. Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. Trials. 2020;21(1):694.","journal-title":"Trials"},{"key":"8936_CR2","unstructured":"National Institute for Health and Care Research. Inclusion now a key condition for NIHR funding | NIHR. 2024. Available from: \nhttps:\/\/www.nihr.ac.uk\/news\/inclusion-now-key-condition-nihr-funding.\u00a0 Cited 9 Jan 2025."},{"key":"8936_CR3","unstructured":"Health Research Authority. HRA and MHRA draft inclusion and diversity guidance. Available from: \nhttps:\/\/www.hra.nhs.uk\/about-us\/news-updates\/hra-mhra-guidance-developing-and-submitting-inclusion-and-diversity-plan\/.\u00a0 Cited 27 Jan 2025."},{"issue":"2","key":"8936_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/QAI.0000000000000842","volume":"71","author":"MJ Curno","year":"2016","unstructured":"Curno MJ, Rossi S, Hodges-Mameletzis I, Johnston R, Price MA, Heidari S. A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2016;71(2):181.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"6","key":"8936_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/archinternmed.2011.31","volume":"171","author":"A Cherubini","year":"2011","unstructured":"Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The Persistent Exclusion of Older Patients From Ongoing Clinical Trials Regarding Heart Failure. Arch Intern Med. 2011;171(6):550\u20136.","journal-title":"Arch Intern Med"},{"issue":"8","key":"8936_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.ejca.2015.01.064","volume":"51","author":"S Treweek","year":"2015","unstructured":"Treweek S, Dryden R, McCowan C, Harrow A, Thompson AM. Do participants in adjuvant breast cancer trials reflect the breast cancer patient population? Eur J Cancer. 2015;51(8):907\u201314.","journal-title":"Eur J Cancer"},{"issue":"1","key":"8936_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/dme.13103","volume":"34","author":"K Khunti","year":"2017","unstructured":"Khunti K, Bellary S, Karamat MA, Patel K, Patel V, Jones A, et al. Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in Type 2 diabetes. Diabet Med. 2017;34(1):64\u20138.","journal-title":"Diabet Med"},{"issue":"232","key":"8936_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijcard.2017.01.018","volume":"1","author":"C Vitale","year":"2017","unstructured":"Vitale C, Fini M, Spoletini I, Lainscak M, Seferovic P, Rosano GM. Under-representation of elderly and women in clinical trials. Int J Cardiol. 2017;1(232):216\u201321.","journal-title":"Int J Cardiol"},{"issue":"1","key":"8936_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1186\/s13063-022-07004-2","volume":"23","author":"V Daitch","year":"2022","unstructured":"Daitch V, Turjeman A, Poran I, Tau N, Ayalon-Dangur I, Nashashibi J, et al. Underrepresentation of women in randomized controlled trials: a systematic review and meta-analysis. Trials. 2022;23(1):1038.","journal-title":"Trials"},{"issue":"7","key":"8936_CR10","doi-asserted-by":"publisher","first-page":"e070666","DOI":"10.1136\/bmjopen-2022-070666","volume":"13","author":"HZ Farooq","year":"2023","unstructured":"Farooq HZ, Apea V, Kasadha B, Ullah S, Hilton-Smith G, Haley A, et al. Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design. BMJ Open. 2023;13(7):e070666-070666.","journal-title":"BMJ Open"},{"key":"8936_CR11","doi-asserted-by":"crossref","unstructured":"Waters L, Sparrowhawk A. Clinical implementation of long-acting antiretroviral treatment in high-income countries: challenges and advantages. Current Opinion in HIV and AIDS. 2022;17(3):121.","DOI":"10.1097\/COH.0000000000000730"},{"issue":"12","key":"8936_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112\u201323.","journal-title":"N Engl J Med"},{"key":"8936_CR13","doi-asserted-by":"crossref","unstructured":"Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. The Lancet HIV. 2021;8(4):e185\u201396.","DOI":"10.1016\/S2352-3018(20)30340-4"},{"issue":"10267","key":"8936_CR14","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2020","unstructured":"Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. The Lancet. 2020;396(10267):1994\u20132005.","journal-title":"The Lancet"},{"issue":"9","key":"8936_CR15","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","volume":"10","author":"MN Ramgopal","year":"2023","unstructured":"Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. The Lancet HIV. 2023;10(9):e566\u201377.","journal-title":"The Lancet HIV"},{"key":"8936_CR16","unstructured":"Czarnogorski M, Garris C, D\u2019Amico R, Flamm J, Sinclair G, Wohlfeiler M, et al. CUSTOMIZE: overall results from a hybrid III implementation-effectiveness study examining implementation of cabotegravir and rilpivirine long-acting injectablefor HIV treatment in US healthcare settings; final patient and provider data. Journal of the International AIDS Society. 2021;24(Generic). Available from: \nhttp:\/\/ovidsp.ovid.com\/ovidweb.cgiT=JS&PAGE=reference&D=emed22&NEWS=N&AN=636605780."},{"issue":"Generic","key":"8936_CR17","first-page":"20","volume":"24","author":"T Lutz","year":"2023","unstructured":"Lutz T, Jeanmaire E, Portilla J, Scherzer J, Trehan R, Pascaul-Bernaldez M, et al. Perceptions of cabotegravir and rilpivirine long-acting (CAB+RPV LA) from patients in the CAB+RPV implementation study in European locations (CARISEL). HIV Medicine. 2023;24(Generic):20\u20131.","journal-title":"HIV Medicine."},{"key":"8936_CR18","unstructured":"Hocqueloux L, Gutner C, DeMoor R, Gill M, Trehan R, D\u2019Amico R, et al. Perspectives on the acceptability, appropriateness, feasibility, barriers, and facilitators from patients receiving cabotegravir + rilpivirine long-acting injectable treatment (CAB+RPV LA): Interim results from the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL). HIV Medicine. 2021;22(Generic):99."},{"issue":"Generic","key":"8936_CR19","first-page":"22","volume":"24","author":"C Wyen","year":"2023","unstructured":"Wyen C, Scherzer J, Jonsson-Oldenbuttel C, Lieb C, Ummard-Berger K, Cordes C, et al. Initiating CAB + RPV LA in a real-world setting - Clinical characteristics and switch reasons from PLHIV and HCP perspectives in the German CARLOS Cohort. HIV Medicine. 2023;24(Generic):22.","journal-title":"HIV Medicine."},{"key":"8936_CR20","unstructured":"UN Joint Programme on HIV\/AIDS (UNAIDS). UNAIDS. 2024. Factsheet 2024: Global HIV statistics. Available from: \nhttps:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf.\u00a0 Cited 7 Jan 2025."},{"key":"8936_CR21","unstructured":"UN Joint Programme on HIV\/AIDS (UNAIDS). AIDSinfo | Global data on HIV epidemiology and response. Available from: \nhttps:\/\/aidsinfo.unaids.org\/. Cited 7 Jan 2025."},{"key":"8936_CR22","unstructured":"UK Health Security Agency. New HIV diagnoses, AIDS, deaths and people in care, England tables. Data to end of December 2023. GOV.UK; 2024. Available from: \nhttps:\/\/www.gov.uk\/government\/statistics\/hiv-annual-data-tables.\u00a0 Cited 7 Jan 2025."},{"key":"8936_CR23","unstructured":"Elias A, Smuk M, Whelan I, Pepper NA, Halim N, Ring K, et al. P024 Inclusion of women, racially minoritised people and older adults in real-world studies evaluating long-acting injectable cabotegravir and rilpivirine: a scoping review. In: Poster Session: Annual BHIVA Spring Conference 2024. Birmingham, United Kingdom; 2024. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/hiv.13628."},{"issue":"1","key":"8936_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/aid.2014.0205","volume":"31","author":"RE Johnston","year":"2015","unstructured":"Johnston RE, Heitzeg MM. Sex, Age, Race and Intervention Type in Clinical Studies of HIV Cure: A Systematic Review. AIDS Res Hum Retroviruses. 2015;31(1):85\u201397.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"8936_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1310\/hct1501-14","volume":"15","author":"JR Castillo-Mancilla","year":"2014","unstructured":"Castillo-Mancilla JR, Cohn SE, Krishnan S, Cespedes M, Floris-Moore M, Schulte G, et al. Minorities Remain Underrepresented in HIV\/AIDS Research Despite Access to Clinical Trials. HIV Clin Trials. 2014;15(1):14\u201326.","journal-title":"HIV Clin Trials"},{"issue":"10","key":"8936_CR26","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"WDF Venter","year":"2020","unstructured":"Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The Lancet HIV. 2020;7(10):e666\u201376.","journal-title":"The Lancet HIV"},{"issue":"9581","key":"8936_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","volume":"370","author":"JV Madruga","year":"2007","unstructured":"Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet. 2007;370(9581):29\u201338.","journal-title":"The Lancet"},{"issue":"6","key":"8936_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/QAD.0000000000003831","volume":"38","author":"N Li","year":"2024","unstructured":"Li N, Zheng HY, He WQ, He XY, Li R, Cui WB, et al. Treatment outcomes amongst older people with HIV infection receiving antiretroviral therapy. AIDS. 2024;38(6):803.","journal-title":"AIDS"},{"issue":"6","key":"8936_CR29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/QAD.0000000000003478","volume":"37","author":"S Zhou","year":"2023","unstructured":"Zhou S, Qi K, Nugent BM, Bersoff-Matcha SJ, Struble K. Participation of HIV-1 infected treatment-naive females in clinical trials and sex differences in efficacy and safety outcomes. AIDS. 2023;37(6):895.","journal-title":"AIDS"},{"issue":"1","key":"8936_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12939-023-01992-6","volume":"22","author":"P Filippone","year":"2023","unstructured":"Filippone P, Serrano S, Campos S, Freeman R, Cluesman SR, Israel K, et al. Understanding why racial\/ethnic inequities along the HIV care continuum persist in the United States: a qualitative exploration of systemic barriers from the perspectives of African American\/Black and Latino persons living with HIV. International Journal for Equity in Health. 2023;22(1):168.","journal-title":"International Journal for Equity in Health"},{"issue":"11","key":"8936_CR31","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1097\/QAD.0000000000002942","volume":"35","author":"R Dhairyawan","year":"2021","unstructured":"Dhairyawan R, Okhai H, Hill T, Sabin CA. Differences in HIV clinical outcomes amongst heterosexuals in the United Kingdom by ethnicity. AIDS. 2021;35(11):1813.","journal-title":"AIDS"},{"issue":"4","key":"8936_CR32","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/S2352-3018(22)00060-1","volume":"9","author":"C Orkin","year":"2022","unstructured":"Orkin C, Apea V. International Women\u2019s Day\u2014how can I help? The Lancet HIV. 2022;9(4):e228\u20139.","journal-title":"The Lancet HIV"},{"issue":"10137","key":"8936_CR33","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/S0140-6736(18)31265-0","volume":"391","author":"T Lancet","year":"2018","unstructured":"Lancet T. Dolutegravir for HIV: a lesson in pregnancy safety research. The Lancet. 2018;391(10137):2296.","journal-title":"The Lancet"},{"issue":"7","key":"8936_CR34","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1016\/S2352-3018(18)30093-6","volume":"5","author":"J Dorward","year":"2018","unstructured":"Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. The Lancet HIV. 2018;5(7):e400\u20134.","journal-title":"The Lancet HIV"},{"key":"8936_CR35","doi-asserted-by":"crossref","unstructured":"Orkin C, Hayes R, Haviland J, Wong YL, Ring K, Apea V, et al. Perspectives of People With HIV on Implementing Long-acting Cabotegravir Plus Rilpivirine in Clinics and Community Settings in the United Kingdom: Results From the Antisexist, Antiracist, Antiageist Implementing Long-acting Novel Antiretrovirals Study.\u00a0Clin\u00a0Infect\u00a0Dis. 2025;80(5):1103\u201313.","DOI":"10.1093\/cid\/ciae523"},{"key":"8936_CR36","unstructured":"World Health Organization. Antiretrovirals in pregnancy research toolkit. Antiretrovirals in pregnancy research toolkit. Available from: \nhttps:\/\/www.who.int\/tools\/antiretrovirals-in-pregnancy-research-toolkit.\u00a0Cited 5 Jun 2024."},{"key":"8936_CR37","unstructured":"UK Public Involvement Standards Development Partnership. UK Standards for Public Involvement. 2019. Available from: \nhttps:\/\/sites.google.com\/nihr.ac.uk\/pi-standards\/standards."},{"key":"8936_CR38","unstructured":"Mwendera C, Kasadha B, Paparini S, Mbewe R. SHARE Research Collaborative. 2022. Guiding Principles for Public Involvement in SHARE health research. Available from: \nhttps:\/\/shareresearch.org.uk\/wp-content\/uploads\/2023\/07\/Guiding-Principles-for-Public-Involvement-in-SHARE-health-research_08.12.2022-FINAL-.pdf."},{"issue":"S1","key":"8936_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/1467-9566.13431","volume":"44","author":"T Rai","year":"2022","unstructured":"Rai T, Hinton L, McManus RJ, Pope C. What would it take to meaningfully attend to ethnicity and race in health research? Learning from a trial intervention development study. Sociol Health Illn. 2022;44(S1):57\u201372.","journal-title":"Sociol Health Illn"},{"issue":"1","key":"8936_CR40","doi-asserted-by":"publisher","first-page":"e13871","DOI":"10.1111\/1467-9566.13871","volume":"47","author":"B Kasadha","year":"2025","unstructured":"Kasadha B, Tariq S, Namiba A, Freeman-Romilly N, Moepi N, Letting G, et al. Hearing the Silence and Silenced: Co-Producing Research on Infant-Feeding Experiences and Practices With Black Women With HIV. Sociol Health Illn. 2025;47(1):e13871.","journal-title":"Sociol Health Illn"},{"issue":"1","key":"8936_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12939-021-01483-6","volume":"20","author":"P Norris","year":"2021","unstructured":"Norris P, Cousins K, Churchward M, Keown S, Hudson M, Isno L, et al. Recruiting people facing social disadvantage: the experience of the Free Meds study. International Journal for Equity in Health. 2021;20(1):149.","journal-title":"International Journal for Equity in Health"},{"issue":"1","key":"8936_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41593-022-01218-y","volume":"26","author":"JA Ricard","year":"2023","unstructured":"Ricard JA, Parker TC, Dhamala E, Kwasa J, Allsop A, Holmes AJ. Confronting racially exclusionary practices in the acquisition and analyses of neuroimaging data. Nat Neurosci. 2023;26(1):4\u201311.","journal-title":"Nat Neurosci"},{"issue":"1","key":"8936_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s13063-024-08291-7","volume":"25","author":"A South","year":"2024","unstructured":"South A, Snowdon C, Burnett E, Bierer BE, Gillies K, Isaacs T, et al. The SHOW RESPECT adaptable framework of considerations for planning how to share trial results with participants, based on qualitative findings from trial participants and site staff. Trials. 2024;25(1):467.","journal-title":"Trials"},{"key":"8936_CR44","unstructured":"Health Research Authority. Communicating study findings to participants: guidance. 2023\u00a0 Available from: \nhttps:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/research-transparency\/informing-participants\/communicating-study-findings-participants-guidance\/.\u00a0Cited 8 Jan 2025."},{"key":"8936_CR45","unstructured":"UK Health Security Agency. National HIV surveillance data tables to end December 2020. 2021 . Available from: \nhttps:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20221003075142\/https:\/www.gov.uk\/government\/statistics\/hiv-annual-data-tables. Cited 18 Nov 2024."},{"key":"8936_CR46","unstructured":"Kitt H, Shah A, Chau C, Okumu-Camerra K, Bera S, Schoemig V, et al. HIV testing, PrEP, new HIV diagnoses and care outcomes for people accessing HIV services: 2024 report. The annual official statistics data release (data to end of December 2023). London: UK Health Security Agency; 2024. Available from: \nhttps:\/\/www.gov.uk\/government\/statistics\/hiv-annual-data-tables\/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2024-report. Cited 14 Nov 2024."},{"issue":"12","key":"8936_CR47","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1007\/s10461-020-02918-x","volume":"24","author":"A Mantsios","year":"2020","unstructured":"Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, et al. Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials. AIDS Behav. 2020Dec 1;24(12):3473\u201381.","journal-title":"AIDS Behav"},{"issue":"8","key":"8936_CR48","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1080\/13691058.2020.1752397","volume":"23","author":"A Mantsios","year":"2021","unstructured":"Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, et al. \u201cI feel empowered\u201d: women\u2019s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain. Cult Health Sex. 2021;23(8):1066\u201378.","journal-title":"Cult Health Sex"},{"issue":"1","key":"8936_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190487","volume":"13","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, Mantsios A, Gorgolas M, Montes ML, Pulido F, Brinson C, et al. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS ONE. 2018;13(1):e0190487.","journal-title":"PLoS ONE"},{"key":"8936_CR50","unstructured":"Aghaizu A, Martin V, Kelly C, Kitt H, Farah A, Latham V, et al. Positive Voices: The National Survey of People Living with HIV. Findings from 2022. Report summarising data from 2022 and measuring change since 2017. [Internet]. London: UK Health Security Agency; 2023. Available from: \nhttps:\/\/www.gov.uk\/government\/publications\/hiv-positive-voices-survey\/positive-voices-2022-survey-report.\u00a0 Cited 23 May 2024."},{"key":"8936_CR51","unstructured":"Office for National Statistics (ONS). Unpaid care by age, sex and deprivation, England and Wales: Census 2021. London: ONS; 2023. Available from: \nhttps:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/socialcare\/articles\/unpaidcarebyagesexanddeprivationenglandandwales\/census2021."},{"issue":"10","key":"8936_CR52","first-page":"204993612312146","volume":"13","author":"P Patel","year":"2023","unstructured":"Patel P, Teichner P, Elliot E, Boffito M, Murray M, Polli JW, et al. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine. Ther Adv Infect Dis. 2023;13(10):20499361231214624.","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"8936_CR53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s13063-021-05276-8","volume":"22","author":"S Treweek","year":"2021","unstructured":"Treweek S, Banister K, Bower P, Cotton S, Devane D, Gardner HR, et al. Developing the INCLUDE Ethnicity Framework\u2014a tool to help trialists design trials that better reflect the communities they serve. Trials. 2021;22(1):337.","journal-title":"Trials"},{"issue":"1","key":"8936_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","volume":"67","author":"J O\u2019Neill","year":"2014","unstructured":"O\u2019Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol. 2014;67(1):56\u201364.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"8936_CR55","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1186\/s13063-024-08625-5","volume":"25","author":"S Treweek","year":"2024","unstructured":"Treweek S, Gillies K, Witham MD, Devane D, Khunti K, Bower P, et al. How should trial teams make decisions about the proportions and diversity of the ethnic groups in their trial? Trials. 2024;25(1):768.","journal-title":"Trials"},{"issue":"10","key":"8936_CR56","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.clon.2022.07.006","volume":"34","author":"Z Iyizoba-Ebozue","year":"2022","unstructured":"Iyizoba-Ebozue Z, Fatimilehin A, Mbanu P, Adeleke S. Reflection on Black and Ethnic Minority Participation in Clinical Trials. Clin Oncol. 2022Oct 1;34(10):674\u20137.","journal-title":"Clin Oncol"},{"key":"8936_CR57","unstructured":"LGBT Foundation. If We\u2019re Not Counted, We Don\u2019t Count: Good practice guide to monitoring sexual orientation and trans status. 2021. Available from: \nhttps:\/\/lgbt.foundation\/wp-content\/uploads\/2023\/12\/If20WeE28099re20Not20Counted20We20DonE28099t20Count20FINAL-2.pdf.\u00a0 Cited 29 Jan 2025."},{"issue":"9","key":"8936_CR58","doi-asserted-by":"publisher","first-page":"e084352","DOI":"10.1136\/bmjopen-2024-084352","volume":"14","author":"S Moorthie","year":"2024","unstructured":"Moorthie S, Oguzman E, Evans S, Brayne C, LaFortune L. Qualitative study of UK health and care professionals to determine resources and processes that can support actions to improve quality of data used to address and monitor health inequalities. BMJ Open. 2024;14(9):e084352.","journal-title":"BMJ Open"},{"issue":"6","key":"8936_CR59","doi-asserted-by":"publisher","first-page":"e002882","DOI":"10.1136\/bmjopen-2013-002882","volume":"3","author":"CL Saunders","year":"2013","unstructured":"Saunders CL, Abel GA, Turabi AE, Ahmed F, Lyratzopoulos G. Accuracy of routinely recorded ethnic group information compared with self-reported ethnicity: evidence from the English Cancer Patient Experience survey. BMJ Open. 2013Jun 1;3(6):e002882.","journal-title":"BMJ Open"},{"issue":"1","key":"8936_CR60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/jamia\/ocab199","volume":"29","author":"LA Cook","year":"2022","unstructured":"Cook LA, Sachs J, Weiskopf NG. The quality of social determinants data in the electronic health record: a systematic review. J Am Med Inform Assoc. 2022;29(1):187\u201396.","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"8936_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/jech.2010.121095","volume":"66","author":"M Petticrew","year":"2012","unstructured":"Petticrew M, Tugwell P, Kristjansson E, Oliver S, Ueffing E, Welch V. Damned if you do, damned if you don\u2019t: subgroup analysis and equity. J Epidemiol Community Health. 2012;66(1):95\u20138.","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"8936_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0895-4356(98)00138-3","volume":"52","author":"WN Kernan","year":"1999","unstructured":"Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified Randomization for Clinical Trials. J Clin Epidemiol. 1999;52(1):19\u201326.","journal-title":"J Clin Epidemiol"},{"issue":"28","key":"8936_CR63","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1002\/sim.9916","volume":"42","author":"E Coart","year":"2023","unstructured":"Coart E, Bamps P, Quinaux E, Sturbois G, Saad ED, Burzykowski T, et al. Minimization in randomized clinical trials. Stat Med. 2023;42(28):5285\u2013311.","journal-title":"Stat Med"},{"key":"8936_CR64","unstructured":"RDN Portfolio | NIHR. Available from: \nhttps:\/\/www.nihr.ac.uk\/support-and-services\/support-for-delivering-research\/research-delivery-network\/RDN-portfolio. Cited 30 Jan 2025."},{"issue":"4","key":"8936_CR65","first-page":"27","volume":"25","author":"S Mollan","year":"2024","unstructured":"Mollan S. Clinical Trial Enrollment Caps: What They Are And When To Use Them. Pharmaceutical Outsourcing. 2024;25(4):27\u20139.","journal-title":"Pharmaceutical Outsourcing"},{"key":"8936_CR66","doi-asserted-by":"publisher","unstructured":"Wermuth P. Participant Recruitment, Screening, and Enrollment. In: Piantadosi S, Meinert CL, editors. Principles and Practice of Clinical Trials. Cham: Springer International Publishing; 2022. p. 257\u201378. Available from: \nhttps:\/\/doi.org\/10.1007\/978-3-319-52636-2_38.","DOI":"10.1007\/978-3-319-52636-2_38"},{"key":"8936_CR67","doi-asserted-by":"crossref","unstructured":"Hinze V, Henshall C, Smith T, Littlejohns J, Collett Z, Jones H, et al. Count Me In: an inclusive approach towards patient recruitment for clinical research studies in the NHS. BMJ Ment Health. 2023;26(1). Available from: \nhttps:\/\/mentalhealth.bmj.com\/content\/26\/1\/e300774 . Cited 10 Jan 2025.","DOI":"10.1136\/bmjment-2023-300774"},{"issue":"6","key":"8936_CR68","doi-asserted-by":"publisher","first-page":"100426","DOI":"10.1016\/j.puhip.2023.100426","volume":"1","author":"K Ray Chaudhuri","year":"2023","unstructured":"Ray Chaudhuri K, Podlewska A, Hui Lau Y, Gonde C, McIntosh A, Qamar MA, et al. Addressing the gap for racially diverse research involvement: The King\u2019s Model for minority ethnic research participant recruitment. Public Health in Practice. 2023Dec;1(6):100426.","journal-title":"Public Health in Practice"},{"issue":"10","key":"8936_CR69","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/s41591-024-03273-3","volume":"30","author":"F Zannad","year":"2024","unstructured":"Zannad F, Berwanger O, Corda S, Cowie MR, Gamra H, Gibson CM, et al. How to make cardiology clinical trials more inclusive. Nat Med. 2024Oct;30(10):2745\u201355.","journal-title":"Nat Med"},{"key":"8936_CR70","unstructured":"Caulfield T. Legal and Ethical Issues Associated with Patient Recruitment in Clinical Trials: The Case of Competitive Enrolment Special Issue: Canadian Governance for Ethical Research Involving Humans: Clinical Trials. Health L Rev. 2004 2005;13(2\u20133):58\u201361."},{"key":"8936_CR71","unstructured":"Epstein S. Inclusion\u202f: The Politics of Difference in Medical Research. Chicago, UNITED STATES: University of Chicago Press; 2007. Available from: \nhttp:\/\/ebookcentral.proquest.com\/lib\/gmul-ebooks\/detail.action?docID=408322 ."},{"issue":"1","key":"8936_CR72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12961-022-00838-x","volume":"20","author":"H Smith","year":"2022","unstructured":"Smith H, Budworth L, Grindey C, Hague I, Hamer N, Kislov R, et al. Co-production practice and future research priorities in United Kingdom-funded applied health research: a scoping review. Health Research Policy and Systems. 2022;20(1):36.","journal-title":"Health Research Policy and Systems"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08936-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:04:34Z","timestamp":1751364274000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08936-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8936"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08936-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BK has received speaker honouraria and consultancy fees from Gilead Sciences, GSK, and ViiV Healthcare. CMO has received honouraria for advisory boards, lectureships and travel sponsorships from Janssen, Gilead Sciences, ViiV Healthcare, MSD and Bavarian Nordic and has received research grants from Janssen, Gilead Sciences, ViiV Healthcare, MSD and AstraZeneca. SP has received research grants from ViiV Healthcare and Gilead Sciences. VA has received speaker fees from ViiV Healthcare, Gilead Sciences and MSD. The remaining authors (RH, MS and NH) have no interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}